U.S. reporting says the Trump administration is preparing a 100% tariff order on some imported patented medications and their active ingredients. Draft documents seen by outlets indicate the policy could be announced as soon as Thursday, though details may change. Biopharma companies with complex supply chains, contract manufacturing footprint, and cross-border ingredient sourcing are likely to view the move as a potential cost shock and timing risk. The prospect also adds uncertainty for near-term launch economics and may accelerate hedging around pricing strategies and sourcing contingencies. For investors, tariff policy is again becoming a headline variable for margins and drug availability, especially for products dependent on specific API routes and formulation inputs.